Description

Sulfobutyl β-Cyclodextrin, Sodium Salt

Sulfobutyl β-Cyclodextrin, Sodium Salt (SBECD) is a high-purity, anionic Cyclodextrin derivative used in pharmaceutical formulations as a solubilizing agent, stabilizer, and complexation carrier for poorly water-soluble or unstable active pharmaceutical ingredients (APIs). Its enhanced aqueous solubility and low toxicity make it ideal for parenteral, oral, and ophthalmic drug delivery systems. SBECD

• Is a modified β-Cyclodextrin with Sulfobutyl ether groups and sodium counterions
• Enhances solubility, stability, and bioavailability of hydrophobic APIs
• Is suitable for injectable, oral, ophthalmic, and intranasal formulations
• Provides high binding affinity with reduced hemolytic and nephrotoxic potential

SBECD is synthesized by selectively attaching Sulfobutyl ether groups to the hydroxyl sites of β-Cyclodextrin, increasing its aqueous solubility while preserving the hydrophobic inner cavity essential for drug complexation. It improves the pharmacokinetic profile of APIs by forming non-covalent inclusion complexes that enhance solubility, reduce irritation, and improve chemical stability.

In pharmaceutical applications, Sulfobutyl β-Cyclodextrin, Sodium Salt is used in:

• Parenteral formulations to solubilize poorly soluble APIs (e.g., antifungals, CNS agents, antineoplastics)
• Oral liquids and solid dispersions for pediatric or modified-release dosage forms
• Ophthalmic and nasal sprays for enhanced local retention and API transport
• Biologic stabilization by protecting peptides or proteins from aggregation and degradation

SBECD is particularly valuable in formulations that require minimal toxicity and excellent solubility, including hospital-use injectables and emergency-use drugs. It is non-immunogenic, non-irritating, and excreted unchanged by the kidneys.

CarboMer supplies Sulfobutyl β-Cyclodextrin, Sodium Salt in sterile and non-sterile grades, with consistent control over the degree of substitution (DS), molecular weight distribution, and endotoxin levels. Product conforms to pharmacopeial specifications (e.g., USP, EP) and is available for clinical and commercial use.

The material is packaged in sealed, low-endotoxin, moisture-protected containers. Available in standard and custom pack sizes to meet both development and commercial manufacturing needs. Minimum order quantities (MOQ), lead times and full regulatory support will e provided upon request.

Each batch undergoes validated testing for identity, assay, degree of substitution, pH, residual solvents, microbial limits, and endotoxins to ensure quality and reproducibility in critical dosage forms.

As with all CarboMer excipients, Sulfobutyl β-Cyclodextrin, Sodium Salt is supported by expert technical formulation consultation, regulatory documentation, and lifecycle support services—helping you advance solubility-enhanced, patient-ready pharmaceutical products with confidence.